NNMT inhibition as a metabolic and epigenetic research target
This comprehensive guide examines exactly how AOD-9604 targets fat cells at the molecular level, covering its selective mechanism on adipocytes, regional fat targeting, the cellular signaling pathways involved, practical protocols, and what makes this peptide uniquely effective for stubborn fat deposits
The SURPASS-3 MRI substudy added another layer, showing tirzepatide actually reduced muscle fat infiltration across all doses, indicating improved muscle quality even as total muscle volume decreased
Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance
High-purity formulation (99%)
By the end of the trial, retatruitde resulted in an average loss of around 24 percent of patients body weight, which amounted to around 58 total pounds
